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Angiogenesis is a hallmark of solid 
tumors. Disruption of tumor angio-
genesis by blocking proangiogenic 
growth factors or shutdown of the 
established tumor blood vessels 
by vascular targeting agents has 
demonstrated therapeutic effects in 
human cancer. The vascular-disrupt-
ing effect can be mediated directly 
by toxic agents or selectively deliv-
ered by antibody or peptide targeting 
(Neri and Bicknell, 2005). The recent 
successful blockade of the VEGF 
pathway in several major cancers 
prolonged survival in phase III clinical 
trials and has encouraged the iden-
tification of new tumor endothelial 
markers (TEMs).
Early attempts to identify tumor 
vascular targets focused on the study 
of in vitro endothelial cell (EC)-iso-
lates using a range of molecular, 
biochemical, and immunological 
techniques. These efforts have led to 
the identification of a limited number 
of molecular markers predominantly 
expressed on angiogenic vessels, 
but in both tumor and physiological 
angiogenesis. With the advent of new 
techniques, a great number of tumor 
endothelial molecules have been 
identified during the last decade. In 
silico methods have been used to 
define new angiogenesis genes such 
as Robo 4 (Huminiecki and Bicknell, 
2000). In vivo phage display has been 
used to deliver peptides that selec-
tively recognize organ-specific and 
tumor endothelium, leading to the 
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Angiogenesis is a hallmark of solid tumors, and disruption of tumor vasculature is an active anti-
cancer therapy in some cases. Several proteins expressed on the surface of tumor endothelium 
have been identified during the last decade. However, due to the expression in both physiological 
and tumor angiogenesis, only a few targets have been developed for clinical therapeutics. By 
thorough SAGE analysis of mouse endothelial cells isolated from various normal resting tissues, 
regenerating liver, and liver-metastasized tumor, Seaman and colleagues in this issue of Cancer 
Cell have demonstrated organ-specific endothelial markers, physiological angiogenesis endothelial 
markers, and tumor endothelial markers and revealed striking differences between physiological 
and pathological angiogenesis.
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identification of aminopeptidase-N 
as a potential marker of tumor vascu-
lature (Ruoslahti, 2002).
In an earlier study from St. Croix 
et al. (2000), global screening of 
gene expression by serial analysis of 
gene expression (SAGE) revealed 79 
transcripts differentially expressed 
between ECs isolated from a human 
colorectal tumor and those isolated 
from its adjacent normal tissue, 
including 46 specifically elevated 
more than 10-fold in tumor-associ-
ated ECs. In situ hybridization showed 
that all nine chosen for the validation 
were prominently expressed in tumor 
ECs but were absent or barely detect-
able in normal ECs. Mouse orthologs 
were also identified, and some were 
strongly expressed in tumor vessels 
and in the developing embryonic vas-
culature, but essentially absent from 
adult normal tissues
Others developed and applied this 
approach further for several tumor 
types, usually comparing tumor 
endothelium with adjacent normal 
tissue endothelium. SAGE analysis of 
human brain ECs revealed 14 glioma 
endothelial markers upregulated in 
ECs isolated from three grade-III/IV 
gliomas compared to ECs from two 
nonneoplastic temporal lobe tissues. 
Of these, 12 are known to be present 
on the cell surface or secreted. In 
situ hybridization demonstrated the 
overexpression of the G protein-cou-
pled receptor RDC1 in both brain 
and colon tumor ECs (Madden et 
al., 2004). SAGE-analysis of purified 
ECs from freshly resected speci-
mens of two invasive breast cancers 
and one normal reduction mammo-
plasty revealed 29 genes that were 
expressed at least 6-fold higher in 
breast tumor ECs than in normal 
breast ECs; five of these were 5-fold 
higher in breast tumor than in both 
colon and brain tumors. HEYL, one 
of the TEMs, was restricted to inva-
sive breast tumor ECs and capable 
of increasing proliferation and reduc-
ing apoptosis of primary ECs in vitro 
(Parker et al., 2004).
van Beijnum et al. (2006) used sup-
pression subtractive hybridization to 
compare gene-expression profiles of 
the ECs isolated from five human colon 
carcinoma, five normal colon tissues 
from the same patients, and five fresh 
placental tissues as well as colorec-
tal tumor-conditioned HUVEC and 
quiescent HUVEC cells. Forty-six 
general angiogenesis genes were 
upregulated in tumor and placental 
ECs compared with patient-matched 
normal ECs; 17 tumor angiogenesis 
genes were overexpressed in tumor 
ECs compared with angiogenic 
(placental) and nonangiogenic ECs. 
Four of these markers (vimentin, 
CD59, IGFBP7, and HMGB1) were 
overexpressed on tumor vascula-
ture at the protein level. Antibodies 
targeting these markers inhibited 
angiogenesis in vitro and in vivo and 
targeting endothelial vimentin in a 
xenograft mouse model markedly 
inhibited tumor growth and tumor 
angiogenesis.
Following the isolation of ECs from 
ten invasive epithelial ovarian can-
cers and five normal ovaries, Lu et al. 
(2007) examined gene-expression dif-
ferences between ovarian tumor ECs 
and normal ECs by microarrays and 
revealed more than 400 differentially 
expressed genes in ovarian tumor 
ECs. Among them, all six validated 
genes were overexpressed in tumor 
ECs at the protein level. Reducing 
the expression of EZH2, Jagged1, or 
PTK2 with siRNA blocked EC migra-
tion and tube formation in vitro.
Figure 1. Schematic Diagram Depicting the Identification of Organ-Specific, Physi-
ological, and Tumor Angiogenesis Markers
Various mouse ECs were isolated from eight normal resting tissues (including brain, heart, kid-
ney, liver, lung, muscle, spleen, and intestine), regenerating liver (24, 48, and 72 hr posthepate-
ctomy), two types of liver-metastasized, and three types of subcutaneously-implanted tumors 
by using CD105 (endoglin) and/or VE-cadherin markers. Numerous SAGE libraries were then 
constructed and sequenced. Thorough analysis of the SAGE Tags revealed 27 brain endothelial 
markers (BEMs) with 20-fold or higher expression in brain ECs compared to other normal tissue 
ECs, 15 liver endothelial markers (LEMs) with 20-fold or higher expression in normal resting liver 
ECs compared to normal ECs from other tissues, 12 angiogenesis endothelial markers (AEMs) 
overexpressed with 10-fold or higher expression in regenerating liver ECs and tumor ECs com-
pared to nonangiogenic ECs of all resting tissues, and 13 tumor endothelial markers (TEMs) 
overexpressed at least 10-fold or higher in tumor ECs compared to normal resting ECs and 
regenerating liver ECs (A). Of the 13 TEMs identified (B), seven of them including CD276 (B7-H3), 
CD137 (4-1BB), MiRP2, Doppel (Prion-PLP), PTPRN (IA-2), CD109, and ankylosis have been 
found to be expressed on the cell surface; PlGF and apelin are secreted angiogenic factors. The 
most differentially expressed of the TEMs was vascular SH2-containing protein (VSCP), followed 
by CD276, ETSvg4 (Pea3), CD137 (including its soluble form, sCD137), and MiRP2. The sizes of 
TEMs are not to scale. Part of panel A is adapted from Figure 1D of Seaman et al. (2007) in this 
issue of Cancer Cell.
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Buckanovich et al. (2007) used 
immunoh is tochemis t r y- gu ided 
laser-capture microdissection and 
transcriptional profiling to character-
ize tumor vascular cells from 21 epi-
thelial ovarian cancers and four nor-
mal ovaries and identified 12 ovarian 
tumor vascular markers that were 
highly expressed in purified tumor 
ECs and localized to tumor vascu-
lature. Some of these markers were 
found to be specifically expressed in 
ovarian cancer but absent in various 
normal tissues, including placen-
tal and female reproductive tissues 
with physiological angiogenesis. 
The expression of STC2, EGFL6, 
and FZD10 in ovarian vascular cells 
was significantly associated with 
decreased disease-free interval.
One major concern arising from 
the above studies is the relative lack 
of data on multiple normal vascular 
beds besides that of tissue adjacent 
to the tumor, which was available for 
obvious surgical reasons. An ideal 
TEM would discriminate between 
tumor angiogenesis and physiologi-
cal or regenerative angiogenesis, 
such as those occurring in female 
reproductive and wound healing tis-
sues, and does not express in any 
type of normal cells. Many of the TEMs 
described so far were also expressed, 
more or less, in physiological angio-
genesis of corpus luteum formation 
and wound healing, or even in normal 
ECs from various organs, though at 
a low level (Bonuccelli et al., 2005; 
Buckanovich et al., 2007; St. Croix et 
al., 2000; van Beijnum et al., 2006). 
Therefore, a major challenge in iden-
tifying tumor endothelium-specific 
markers seems to be obtaining suf-
ficiently pure EC populations from 
natural tumors, organ-matched nor-
mal and regenerative tissues, and 
other resting tissues.
Seaman and colleagues extend 
their previous studies and now pro-
vide new information to answer these 
issues on organ-specific endothelial 
markers, angiogenesis endothelial 
markers (AEMs), and TEMs (Seaman 
et al., 2007, this issue of Cancer Cell) 
(Figure 1). This time they used mouse 
models and comprehensively SAGE-
analyzed gene-expression profiles in 
mouse ECs that were isolated from 
various normal tissues, regenerating 
liver, and liver-metastasized tumors 
as well as subcutaneously implanted 
tumors. Twenty-seven brain endothe-
lial markers and 15 liver endothelial 
markers were identified to be highly 
expressed in resting brain or liver 
ECs compared to normal ECs from 
other tissues. In addition, 12 AEMs 
were overexpressed with 15- to 100-
fold higher in regenerating liver ECs 
compared to nonangiogenic ECs, 
and most of AEMs have expected 
roles in cell-cycle control. AEMs 
were also upregulated in tumor ECs, 
highlighting the overlapping proc-
esses in physiological and tumor 
angiogenesis.
However, 13 TEMs were expressed 
at least 10-fold higher in tumor ECs 
than in normal ECs and regenerating 
liver ECs, of which seven TEMs were 
found to be cell surface receptors. 
Validation of the top nine TEMs by in 
situ hybridization showed that each of 
them was expressed in the ECs of var-
ious tumor types. Further investiga-
tion of CD276, the most differentially 
expressed TEM, with multiple human 
tumor samples revealed that CD276 
was highly expressed in tumor ECs of 
various tumor types and also in tumor 
cells in some cases. Thus, this study 
revealed not only organ-specific and 
angiogenesis-specific EC markers 
but also striking differences between 
physiological and pathological angio-
genesis at the molecular level, which 
are potentially important for the devel-
opment of tumor-specific vascular tar-
geting therapy.
Nevertheless, several issues 
remain to be further investigated. 
The gene-expression profiling of 
the ECs from xenograft or allograft 
tumors could be very different from 
those in endogenously formed pri-
mary and metastatic tumors. Moreo-
ver, transcriptional profiling at a later 
stage of regenerating liver or from 
chronically inflamed tissue or inflam-
matory responses is likely to be more 
informative when compared to tumor 
angiogenesis since tumors represent 
“unhealed wounds” and are chronic. 
The threshold for analysis of these 
genes was set at 10-fold, but analy-
sis of genes with lower differential 
may be just as important. Splice 
variants, which have been shown to 
be important for other vascular tar-
gets such as fibronectin and CD44, 
will need to be analyzed. The extent 
of heterogeneity of the TEM profile, 
such as expression at different sites 
of metastasis, interindividual vari-
ation, and variation from tumor to 
tumor, will be important to evaluate. 
Clearly identifying organ-specific EC 
markers in addition to those of brain 
and liver is also important. In vivo 
imaging studies should help resolve 
some of these issues.
The most important point per-
haps is still the specificity of these 
TEMs. Four of them (CD276, CD137, 
PTPRN, and CD109) had been shown 
to be involved in regulating inflam-
matory or autoimmune responses. 
CD276 can be induced on T cells, B 
cells, and dendritic cells by various 
cytokines. Therefore, more cautious 
evaluation of these TEMs for their 
tissue/cell specificity and biological 
function should be warranted prior 
to developing these TEMS as thera-
peutic targets clinically.
Could some of these markers be 
mechanistic? What is their role in 
angiogenesis and cell trafficking, 
e.g., attracting endothelial progeni-
tors and immune cells? What are 
the mechanisms for their upregu-
lation? Could they be regulated by 
cytokines secreted by tumor, which 
activate distant sites of metastasis 
to prepare the “soil”? If so, early 
therapy could be used to prevent 
establishing growth of microme-
tastasis. The findings of Seaman et 
al. (2007) provide a great resource 
for further investigation of these 
issues.
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